Richmond Pharmacology

London SE1 1YR

5 studies enrolling now · 9 studies all time

What they study most

Amyloid Cardiomyopathy, Amyloidosis, Cardiomyopathies, Cardiovascular, Dyslipidemias, Heart Diseases, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Hypercholesterolaemia, Hypertriglyceridemia, Lipid Disorder, Metabolic Disease

Studies at this site

• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias — Recruiting now
• A Study Assessing HMB-002 in Participants With Von Willebrand Disease — Recruiting now
• A Study of Bleeding and Treatment in Participants With Von Willebrand Disease — Recruiting now
• MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) — Recruiting now
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) — Enrolling by invitation
• CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study — Running, not enrolling
• CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) — Running, not enrolling
• Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy — Completed
• A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis — Completed